PCSK9 inhibitor monoclonal antibodies (PCSK9i mAb) markedly lower rates of ischaemic cardiovascular events and all-cause mortality in patients with established atherosclerotic cardiovascular disease (ASCVD) without prior ischaemic events.
Five-year outcome analyses reveal a 30.9% relative risk reduction (RRR) and 7.8% absolute risk reduction (ARR) in the primary composite endpoint with PCSK9i treatment.
Initiation of PCSK9i mAb resulted in substantial LDL-C reductions (mean absolute reduction 63.1 mg/dL, 53.6% decrease from baseline), demonstrating potent lipid-lowering in a real-world setting.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
